Hangzhou Tigermed Consulting Co., Ltd
300347
株式のランク
#3218
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides... Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People’s Republic of China.
株価
$7.44
時価総額
$5.49B
変化（1日）
-2.99%
変化（1年）
-0.42%
国
CN
取引 Hangzhou Tigermed Consulting Co., Ltd (300347)
カテゴリー
Healthcare
Hangzhou Tigermed Consulting Co., Ltd（300347）の発行済株式数
June 2026 時点の発行済株式数 836.35M
Hangzhou Tigermed Consulting Co., Ltd の最新の財務報告および株価によると、現在の発行済株式数は 836.35M です。December 2024 の終わりには、同社は 863.04M 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Hangzhou Tigermed Consulting Co., Ltd（300347）の発行済株式数の履歴（2009 ～ 2026）
各年末時点の発行済株式数
| 年 | 発行済株式数 | 変化 |
|---|---|---|
| 2026 (TTM) | 836.35M | -2.04% |
| 2025 | 853.74M | -1.08% |
| 2024 | 863.04M | -0.22% |
| 2023 | 864.95M | -0.69% |
| 2022 | 870.96M | 9.01% |
| 2020 | 798.98M | 7.27% |
| 2019 | 744.81M | -0.63% |
| 2018 | 749.50M | 1.26% |
| 2017 | 740.14M | 5.24% |
| 2016 | 703.26M | 8.00% |
| 2015 | 651.16M | 0.30% |
| 2014 | 649.23M | 1.26% |
| 2013 | 641.15M | 20.16% |
| 2012 | 533.60M | 10.72% |
| 2011 | 481.93M | 1.32% |
| 2010 | 475.64M | 16.86% |
| 2009 | 407.01M | 0.00% |
類似企業や競合他社の発行済株式数
| 企業 | 発行済株式数 | 差 | 国 |
|---|---|---|---|
| 253.90M | -69.64% |
US
|
|
| 396.00M | -52.65% |
US
|
|
| 478.91M | -42.74% |
AU
|
|
| 0.00 | -100.00% |
BE
|
|
| 62.19M | -92.56% |
NL
|
